Full-Service CROs
CROs managing complete clinical trial programs across all phases.
Market snapshot
These figures describe Clinical Research Organizations (CRO) (4.9.2), the segment that Full-Service CROs sits within. They are not figures for Full-Service CROs on its own.
Within biotech R&D (NAICS 541714, a broad ~$91B research category) and life-sciences services; CROs are not cleanly separated, so the segment is not separately sized here.
Business model & economics
Revenue model
Fee-for-service and full-service trial-management contracts
Key economics
- Recurring revenue
- High
- EBITDA margin
- 15–25%
- Capex intensity
- Low
multi-year program relationships
Characteristics
- Large, consolidated drug-development outsourcing market.
- Trial complexity and R&D outsourcing drive demand.
- Sensitive to the biotech funding cycle.
Geographic concentration
Clinical research organizations concentrate around the life-sciences clusters of Massachusetts and the Maryland biotech corridor, with Delaware and California close behind.
U.S. Census Bureau, 2022 Statistics of U.S. Businesses (firms by state), NAICS 541714. Concentration shown by location quotient.
M&A deal context
Who’s acquiring
- CRO majors
- Life-sciences-services consolidators
- PE-backed platforms
What’s driving deals
- Consolidation around full-service CRO platforms.
- Biopharma R&D-outsourcing growth.
- Trial-complexity and capability demand.
Find Full-Service CROs acquisition targets
Search Acquisera’s index for companies classified under Full-Service CROs (4.9.2.1) and build a targeted deal pipeline.
Search companies